Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Firm Capable Of Producing Stem Cells For All Chinese Pediatric Leukemia Patients

This article was originally published in PharmAsia News

Executive Summary

Tianjin Angsai Cell and Genome Project, China's first umbilical stem-cell bank, says it is now able to produce stem cells on a large scale. The company has nearly 5,000 samples of mesenchymal umbilical-cord stem cell samples in stock. A spokesman for the Ministry of Health said a supply of 70,000 to 100,000 samples could treat all of China's pediatric leukemia patients who rely on cell transplants for their only cure. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel